BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence